NeuroVive Pharmaceutical AB (publ): report from EGM

Today, 31 March 2016, an extraordinary general meeting was held in NeuroVive
Pharmaceutical AB (publ) (“NeuroVive” or the “Company”). A summary of the
resolutions follows. All resolutions were passed with the required majority.
Approval of the board of directors’ resolution to issue shares and warrants with
preferential rights for existing shareholders
The EGM resolved to approve the board of directors’ resolution as of 28 February
2016 to issue not more than 17,984,960 shares and to issue not more than
2,248,120 warrants of series 2016/2017:1 and not more than 2,248,120 warrants of
series 2016/2017:2 new shares with preferential rights for existing shareholders
(the “New Issue”). The New Issue shall be conducted through issuance of so
called Units.

The terms and conditions governing the New Issue mean that shareholders of the
Company are entitled to, with preferential rights, subscribe for Units as
follows. One (1) existing share in the Company entitles to one (1) unit right.
Fourteen (14) unit rights entitle to subscription of one (1) unit, consisting of
eight (8) new shares, one (1) warrant of series 2016/2017:1 and one (1) warrant
of series 2016/2017:2.

Upon full subscription of the New Issue and upon full exercise of the warrants,
the share capital will increase with SEK 1,124,060.

The record date of the New Issue is 8 April 2016 and the subscription period is
18 April – 2 May 2016. The subscription price per unit is SEK 42, corresponding
to a subscription price of SEK 5.25 per share. The warrants are issued without
consideration.

One (1) warrant of series 2016/2017:1 entitles to subscription of one (1) share
in the Company at a subscription price of SEK 6.50. Subscription for shares in
the Company on the basis of warrants of series 2016/2017:1 may take place during
the period from and including 2 January 2017 up to and including 28 February
2017.

One (1) warrant of series 2016/2017:2 entitles to subscription for one (1) share
in the Company at a subscription price of 70% of the Company’s volume-weighted
average share price on Nasdaq Stockholm over 15 trading days before the
beginning of the subscription period, subject to a minimum of SEK 8.
Subscription for shares in the Company on the basis of warrants of series
2016/2017:2 may take place during the period from and including 1 June 2017 up
to and including 30 June 2017.

Upon full subscription of the New Issue, the Company will raise approximately
SEK 94.4 million before issue expenses. Full exercise of the warrants will raise
at least a further SEK 32.6 million for the Company. The proceeds from the New
Issue will be used for NeuroVive’s continued operations in drug development,
clinical trials and partnership activities.

To enable the New Issue, the EGM also resolved to amend the limits of the share
capital in the articles of association from minimum SEK 591,000 and maximum SEK
2,364,000 to minimum SEK 1,500,000 and maximum SEK 6,000,000, and to amend the
limits of the number of shares in the articles of association from minimum
11,820,000 and maximum 47,280,000 to minimum 30,000,000 and maximum 120,000,000.

About NeuroVive
NeuroVive Pharmaceutical AB (publ) is a pioneer in mitochondrial medicine and a
company committed to the discovery and development of highly targeted candidates
that preserve mitochondrial integrity and function in areas of significant
therapeutic need. NeuroVive’s business approach is driven by value-adding
partnerships with mitochondrial research institutions and commercial partners
across the globe. NeuroVive’s portfolio consists of two clinical projects in
acute kidney injury (AKI) and traumatic brain injury (TBI) with candidates in
clinical and preclinical development and two drug discovery platforms. The
NeuroSTAT® product has orphan drug status in Europe and in the US for treatment
of moderate to severe traumatic brain injury and is currently being evaluated in
a study, CHIC. Ciclosporin (CicloMulsion®) is being evaluated in an on-going
study, CiPRICS, in acute kidney injury during major surgery. NeuroVive’s shares
are listed on Nasdaq, Stockholm, Sweden

For Investor Relations and media questions, please contact:
Christine Tadgell, NeuroVive, Tel: +46 (0)46-275 62 21 or ir@neurovive.com

NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund
Tel: +46 (0)46 275 62 20 (switchboard), Fax: +46 (0)46 888 83 48
info@neurovive.com, www.neurovive.com

NeuroVive Pharmaceutical AB (publ) is obligated to publish the information
contained in this press release in accordance with the Swedish Securities Market
Act. This information was provided to the media for publication at 13.00 CET on
31 March 2016.
NeuroVive Pharmaceutical AB (publ) - the mitochondrial medicine company. The
company is listed on NASDAQ OMX Stockholm, Small Cap, under the ticker symbol
NVP. The share is also traded on the OTC market in the US. NeuroVive
Pharmaceutical (OTC: NEVPF) trades on the OTC Pink Market. Investors can find
Real-Time quotes and market information for the company
at www.otcmarkets.com/stock/NEVPF/quote (http://htt//www.otcmarkets.com/stock/NE
V 
PF/quot)